Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX in EU

Auxilium Pharmaceuticals, Inc. AUXL today announced that the Company received a $7.5 million regulatory milestone from Pfizer, Inc. PFE following the first sale of XIAPEX in Germany, a major EU market. XIAPEX is now available for sale in the United Kingdom, Germany, Denmark, Sweden, Finland, Norway and Austria. XIAPEX is a new non-surgical treatment option for Dupuytren's contracture in adult patients with a palpable cord and is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture.